Safety and Efficacy of Intracranial Thrombus Aspiration Catheter in the Treatment of Acute Large-vessel Occlusive Stroke

Acute Ischemic Stroke Clinical Trial

Official title:

A Prospective, Multi-center, Single-arm Objective Performance Criteria Trial to Evaluate the Safety and Efficacy of Intracranial Thrombus Aspiration Catheter in Treatment of Acute Large-vessel Occlusive Stroke

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05101668
• Other study ID #: SINOMED ADPAT
• Status: Terminated
• Phase: N/A
• Start date: October 8, 2021
• Est. completion date: August 17, 2022

Study information

• Verified date: April 2023
• Source: Sinomed Neurovita Technology Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A prospective, multicenter, single-arm objective performance criteria trial to investigate the safety and efficacy of SINOMED ADPAT for Recanalization Therapy in acute large-vessel occlusive stroke.

Description:

This study plans to recruit 164 patients with acute intracranial large-vessel occlusion within 24 hours time window. The Primary endpoint is the instant recanalization rate of target vessel after operation. Secondary efficacy endpoints will include: 1) immediate recanalization rate of the first pass of aspiration; 2) the recanalization time of the target vessel blood flow; 3) the improvement of the postoperative NIHSS score; 4) the ratio of good neurological function (mRS 0-2 points) at 90 days; 5) the success rate of device; 6) the success rate of operation; 7) The proportion of rescue therapy. Safety endpoints will include: 1) the incidence of symptomatic intracranial hemorrhage within 24 hours after operation; 2) all-cause death and stroke-related mortality at 90 days; 3) stroke recurrence rate within 90 days after operation; 4) surgery-related complications; 5) adverse events; 6) serious adverse events; 7) Device defection rate

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 26
• Est. completion date: August 17, 2022
• Est. primary completion date: July 18, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Aged = 18 years and = 85 years;

2. Acute ischemic stroke, patients with anterior / posterior circulation vessel occlusion (intracranial segment of internal carotid artery or M1 or M2 segment of middle cerebral artery) confirmed by digital subtraction angiography (DSA);

3. Premorbid modified Rankin Scale(mRS)<2 and Pre-operation NIHSS score =6;

4. The patients should receive endovascular treatment within 24 hours:

1. If the treatment could happen within 6 hours, the patient should have an CT or MR

2. If the treatment could happen 6-24 hours, the patient should have an CT or magnetic resonance (MR), have an ASPECTS = 6 points. If immediate CT perfusion imaging or MR perfusion imaging is feasible, CT perfusion (CTP) or magnetic resonance perfusion (MRP) should be performed at the same time to assist in the evaluation of the infarct core.

5. Written informed consent obtained from patient or patient's legally authorized representative.

Exclusion Criteria:

1. Large (more than one-third of the MCA) regions of clear hypodensity on the baseline neuroimaging or significant mass effect with midline shift;

2. Any type of intracranial hemorrhage or subarachnoid hemorrhage (only microbleeds are allowed, or judge from surgeon's clinical experience) by neuroimaging;

3. Proven Simultaneous acute occlusion of both carotid artery systems, and Proven tandem lesion of simultaneous occlusion of intracranial and extracranial vessels by neuroimaging;

4. Occlusion of the common carotid artery,and known or suspected chronic occlusion of target vessel;

5. Patients with consciousness disorder with posterior circulation vascular occlusion, NIHSS score is 3 points (1a=3);

6. Proven intracranial artery occlusion due to arterial dissection or arteritis by neuroimaging;

7. Arterial tortuosity and other problems that would prevent the device from reaching the target vessel;

8. Known to have one or more of the following allergies/resistances or contraindications:

antiplatelet drugs/anticoagulant drugs/contrast agents and/or anesthetics;

9. Known allergies to medical devices and related products (allergy to materials such as nickel-titanium metal or its alloys);

10. Active bleeding or known bleeding tendency (such as: anticoagulant therapy or coagulation dysfunction before surgery, international normalized ratio (INR)>3.0);

11. Baseline platelet counts<40×10^9/L;

12. Severe heart, liver or kidney failure and other serious or terminal illness;

13. Accompanied by ST-segment elevation myocardial infarction or severe infection (endocarditis or sepsis);

14. Hypertension that cannot be controlled after treatment (Baseline blood pressure>185/110 mmHg);

15. Baseline blood glucose < 2.7 or > 22.2 mmol/L. after treatment;

16. Life expectancy less than 3 months;

17. Women who are pregnant or planning to pregnancy during half a year by taking medical history);

18. Dementia or psychiatric disease that would confound the neurological or functional evaluations;

19. Current participation in another drug or device research;

20. Other special situations which the researchers believe to be not suitable for enrollment.

Related Conditions & MeSH terms

• Acute Ischemic Stroke
• Aspiration
• Intracranial Thrombosis
• Ischemic Stroke
• Stroke

Intervention

Device:
• Intracranial Thrombosis Aspiration Catheter
Direct Aspiration

Locations

Country	Name	City	State
China	Qingwu Yang	Chongqing
China	LIUZHOU People's Hospital	Liuzhou
China	Jinzhao Liu	Puyang
China	Zhongnan Hospital of Wuhan University	Wuhan
China	Xiangtan Central Hospital	Xiangtan
China	Xiang Yang No.1 Peoples Hospital	Xiangyang

Sponsors (1)

Lead Sponsor	Collaborator
Sinomed Neurovita Technology Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Instant recanalization rate of target vessel after operation	Instant recanalization rate (mTICI 2b-3) of target vessel after operation	Last aspiration
Secondary	Instant recanalization rate of target vessel after the first aspiration	Instant recanalization rate (mTICI 2b-3) of target vessel after the first aspiration	First aspiration
Secondary	The recanalization time of the target vessel blood flow	The recanalization (mTICI 2b-3) time of the target vessel blood flow	Procedure time (femoral artery puncture to recanalization)
Secondary	The improvement of the postoperative NIHSS score the improvement of the postoperative NIHSS score	NIH Stroke Scale/Score (NIHSS):Calculates the NIH Stroke Scale for quantifying stroke severity.	Change in NIHSS score at preoperative?24(-6/+24) hours?7±2 days or discharge
Secondary	Proportion of good neurological function (mRS 0-2)	The modified Rankin Scale/Score (mRS) : scores of 0 to 2 were defined as good neurological function (treatment success)	90 days
Secondary	The success rate of device	The intracranial thrombus aspiration catheter was successfully delivered to the occluded segment of the blood vessel and then successfully released, and suction was performed, and the delivery system was successfully withdrawn.	Intraoperative
Secondary	The success rate of operation	The success of recanalization after the final treatment (mTICI 2b-3, allowing the use of rescue therapy)	End of Procedure
Secondary	The incidence of symptomatic intracranial hemorrhage	Through Heidelberg Bleeding Classification to evaluate the intracranial hemorrhage (National Institutes of Health Stroke Scale (NIHSS) score of =4 points)	24(-6/+24) hours
Secondary	All-cause death and stroke-related mortality	All-cause death and stroke-related mortality	90 days
Secondary	The rate of Stroke recurrence	The existence of clear imaging evidence to confirm that the target vessel is occluded again, which leads to an ischemic stroke event.	90 days
Secondary	Procedure-related complications	Procedure-related complications: including arterial rupture, arterial dissection, distal thromboembolism, vascular puncture site complications, etc	Intraoperative
Secondary	Adverse events and serious adverse events	Any adverse events and serious adverse events are associated with clinical trials in human	During the clinical trials
Secondary	The rate of device defection	Device defection	Intraoperative